MedTrace Logo

Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together

NCT00352066 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2011-06-23

No results posted yet for this study

Summary

The aim of the study is to see if apricitabine or tipranavir affect the levels of each other in the blood (pharmacokinetic interaction) when they are dosed together.

Conditions

  • HIV Infection

Interventions

DRUG

apricitabine

Sponsors & Collaborators

  • Avexa

    lead INDUSTRY

Principal Investigators

  • Susan W Cox, Ph D · Avexa

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2006-08-31
Completion
2006-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00352066 on ClinicalTrials.gov